Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 Clinical Trial Not Allowed)

Background
The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies. The National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) are the participating organizations issuing this grant.

Grant Details
The grant aims to support mechanistic studies of early Mtb infection in the airway and lung, focusing on identifying immunomodulatory therapeutics, host-pathogen interactions, and the impact of HIV co-infection on immune mechanisms during early Mtb infection. The primary focus should be on mechanisms of Mtb-induced immune evasion/disruption of immunity-related cell functions and interactions among myeloid, lymphoid, and non-immune cells within the airway and lung tissue that determine disease progression vs. cessation. The maximum project period is 5 years.

Eligibility Requirements
Eligible applicants include higher education institutions, nonprofits, for-profit organizations, state and local governments, federal agencies, U.S. territories or possessions, foreign institutions, and other entities as described in the NIH Grants Policy Statement. Individuals from diverse backgrounds are encouraged to apply.

Period of Performance
The earliest start date for the project is October 11, 2023. The project must be completed within a maximum period of 5 years.

Grant Value
NIAID intends to commit $2,000,000 in FY 2024 to fund 3 to 4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project.